Why the study?
Does the VentrAssist implantable rotary blood pump cause minimal hemolysis compared to control in vitro?
Does the VentrAssist implantable rotary blood pump cause minimal hemolysis compared to control in vitro?
The VentrAssist implantable rotary blood pump demonstrates minimal hemolysis in vitro, which is improved by surface finish but unaffected by running clearance.
Answers are grounded in this paper and cite their sources.
Minimal hemolysis in this in vitro model supports device refinement; leaves open clinical translation pending in vivo human data.
The VentrAssist implantable rotary blood pump (IRBP) is an implantable centrifugal blood pump with a hydrodynamically suspended impeller; optimal efficiency requires small running clearances (70-300 microm). The effect of running clearance and polish on hemolysis was evaluated in vitro. Three different human blood suspensions were compared: phosphate buffered saline (PBS), plasma volume expander (Hemaccel), and whole blood. The test conditions were: blood hematocrit 30%, flow rate 5 L/min, pressure across pump 100 mm Hg, 6 h flow period, and 37 degrees C. Normalized Index of Hemolysis (NIH) for the Biomedicus BP-80, used as a control, was: 0.0040 +/- 0.0023 (n = 9; x +/- SD) and 0.00014 +/- 0.00009 (n = 5) for pooled blood suspensions in PBS and Hemaccel respectively, and 0.00053 +/- 0.0002 (n = 3) in whole blood. Hemolysis was reduced by improved surface finish and unaffected by running clearance. NIH for the VentrAssist IRBP with 0.2 microm Ra surface finish was 0.000167 +/- 0.00007 (n = 4) g/100 L in whole human blood, demonstrating minimal hemolysis.
No takes yet. Share an insight, caveat, or question.
James et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: